Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

NCT02134925 PHASE2 ACTIVE_NOT_RECRUITING Results posted

This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	110
Start date	Mon Jun 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Colorectal Adenoma
• Colorectal Adenoma With Severe Dysplasia
• Colorectal Carcinoma
• Colorectal Tubulovillous Adenoma

Interventions

• Laboratory Biomarker Analysis
• MUC1 Peptide-Poly-ICLC Vaccine
• Quality-of-Life Assessment
• Saline

Countries

Puerto Rico, United States